DATE: October 19, 2017
TIME: 08:00am PDT, 11:00am EDT

Recent FDA approval of the first Chimeric Antigen Receptor T cell (CAR-T) therapy offers cancer patients more promise than ever for curative effects. However, many technical challenges in T cell gene delivery still remain in order for this therapy to become a standard of care practice. In this webinar, we will highlight the different viral and non-viral delivery approaches used in T cell engineering for cell and gene therapy applications including:

• New solution for small-to-large scale serum-free, suspension lentiviral production – LV-MAX™ Lentiviral Production System
  • Platform development process using Design of Experiment (DOE) methodologies
  • High-throughput to large scale bioreactor protocols
  • Cost benefits of this system over current methods
• Novel gene editing tools for primary T cells
  • New potent gene editing tools to increase knock-in and knock-out efficiency
  • Addressing non-viral delivery barriers through protocol optimization

Learning Objectives:

• Current industry trends and challenges of cell and gene therapy manufacturing
• Benefits of innovative new upstream technologies for virus generation in suspension